What is AbbVie's current dividend yield?

AbbVie's dividend yield is approximately 4.5%.

What is Pfizer's current dividend yield?

Pfizer's dividend yield is approximately 5.8%.

What are the main risks facing AbbVie?

The main risk is the patent expiration of Humira, exposing its revenue to biosimilar competition.

What are the main risks facing Pfizer?

The main risks are declining COVID product revenues and a high payout ratio that may threaten dividend sustainability.

AbbVie vs. Pfizer: Which Dividend Stock Is Better Today?

Both AbbVie and Pfizer are leading dividend stocks in healthcare. This analysis reviews their dividend profiles, growth prospects, and risks to help investors make an informed decision.

AbbVie (ABBV) and Pfizer (PFE) are among the top dividend stocks in the healthcare sector, with long histories of stable payouts. However, differing business models and challenges raise the question: which is the better choice today?

Dividend Comparison

AbbVie offers a dividend yield of approximately 4.5%, while Pfizer's yield is around 5.8%. However, the sustainability of these dividends depends on each company's financial performance.

AbbVie (ABBV)

Dividend Yield: ~4.5%
Payout Ratio: About 50% of earnings, indicating good sustainability.
Risks: Patent expiration of Humira, which accounts for a significant portion of revenue.

Pfizer (PFE)

Dividend Yield: ~5.8%
Payout Ratio: Relatively high (over 80%) due to declining earnings post-COVID.
Risks: Dependence on COVID products (Comirnaty vaccine and Paxlovid treatment) with waning demand.

Growth Prospects

AbbVie is diversifying its portfolio through acquisitions (e.g., Allergan) and developing new drugs to offset Humira's decline. Pfizer is strengthening its pipeline via deals (e.g., Seagen acquisition) and advancing new therapies.

Risks

AbbVie: Humira patent expiration and competition from biosimilars.
Pfizer: Declining COVID revenues and high payout ratio, which may limit dividend growth.

What This Means for Investors

Both stocks offer attractive dividend yields, but AbbVie may be more sustainable long-term due to its lower payout ratio and ongoing business diversification. Pfizer offers a higher yield but with greater risk regarding dividend sustainability. Investors should evaluate their investment goals and risk tolerance before choosing.